Company profile: Proteovant Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology solutions utilizing protein degradation research to develop medicines for diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Proteovant Therapeutics
Biomea Fusion
HQ: United States
Website
- Description: Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomea Fusion company profile →
NovelStem
HQ: United States
Website
- Description: Provider of diagnostic technology and biotech solutions, including NewStem Diagnostic for early detection of anti-cancer drug resistance aiding targeted cancer treatments, NewStem Therapeutics using proprietary HhESCs for drug and gene screenings to identify genes and drugs for genetic and epigenetic disorders, NewStem Cell Growth Media to improve hPSC growth, and Net Force, a publishing franchise on digital crime, espionage, and crypto.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovelStem company profile →
Vortex Biosciences
HQ: United States
Website
- Description: Provider of oncology diagnostics integrating cancer biology, microfluidic engineering, and informatics to isolate and characterize circulating tumor cells (CTCs). Offers the VTX-1 Liquid Biopsy System for label-free isolation of viable CTCs from blood, CTC enrichment using disposable cartridges, CTC analysis and downstream assays, and cell handling in formats compatible with different workflows.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vortex Biosciences company profile →
SpringWorks Therapeutics
HQ: United States
Website
- Description: Provider of targeted oncology therapies for cancer and rare diseases, focused on innovative treatments for unmet needs. Portfolio includes nirogacestat, an oral gamma secretase inhibitor for desmoid tumors and in evaluation for ovarian granulosa cell tumors and multiple myeloma; mirdametinib, a MEK inhibitor for NF1-associated plexiform neurofibromas; brimarafenib (BGB-3245), a RAF fusion/dimer inhibitor; and SW-682, a TEAD inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SpringWorks Therapeutics company profile →
Clarient
HQ: United States
Website
- Description: Provider of cancer diagnostic testing and oncology diagnostic services in the United States, partnering with local pathologists and oncologists to bring the standard of care back to their communities, using multiple technologies to clarify complex problems, help diagnose cancer cases, and provide insight.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarient company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Proteovant Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Proteovant Therapeutics
2.2 - Growth funds investing in similar companies to Proteovant Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Proteovant Therapeutics
4.2 - Public trading comparable groups for Proteovant Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →